Evidence map›Paper›PMID 27015568›Full record

ArticlePloS one2016

Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma.

Andrew Hendifar, Arsen Osipov, Jasleen Khanuja, Nicholas Nissen, Jason Naziri, Wensha Yang, Quanlin Li, Richard Tuli

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 52 citations in OpenAlex.

  1. Associations of corticosteroid therapy with weight change and appetite in patients with advanced pancreatic cancer - a post hoc analysis from the MISTRAL trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. The pancreatic cancer genome revisited.Nature reviews. Gastroenterology & hepatology · 2021
    Review
  16. Article
  17. Symptom Management in Pancreatic Cancer.Current treatment options in oncology · 2021
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Andrew HendifarDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.
Arsen OsipovDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.
Jasleen KhanujaDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.
Nicholas NissenDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.
Jason NaziriDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.
Wensha YangDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.
Quanlin LiDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.
Richard TuliDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.
Cedars-Sinai Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is a known risk factor for PDA and recent reports suggest obesity has a negative impact on clinical outcomes in patients with PDA. Pretreatment body mass index (BMI) and serum albumin (SA) have been shown to be associated with worse overall survival in patients with advanced and metastatic PDA. However, minimal data exists on the impact of BMI and SA on perioperative and long-term clinical outcomes in patients with early-stage resected PDA. Herein, we report on the impact of these variables on perioperative clinical outcomes, overall survival (OS) and disease free survival (DFS) in patients with resected PDA. With IRB approval, we evaluated 1,545 patients with PDA treated at a single institution from 2007-2013 and identified 106 patients who underwent upfront resection with curative intent. BMI and SA were calculated preoperatively and at the time of last clinical evaluation. Influence of preoperative BMI, SA, change in either variable, and influence of other clinical and pathologic variables on perioperative morbidity and mortality was assessed. The impact of these variables on DFS and OS was assessed with cox regression modeling and ANOVA. Actuarial estimates for DFS and OS were calculated using Kaplan-Meier methods. Median follow up time was 16 months (3-89). Mean age was 68 years. Median survival was 14 months (3-65) and median time to recurrence was 11 months (1-79). Length of hospital stay was associated with BMI (p = .023), change in BMI (p = .003) and SA (p = .004). Post-operative transfusion rate was associated with SA (p = .021). There was a strong correlation between BMI change and positive margin (p = .04) and lymph node status (p = .01). On multivariate analysis, change in SA (p = .03) and node positivity (p = .008) were associated with decreased DFS. Additionally, preoperative SA (p = .023), node positivity (p = .026) and poor differentiation (p = .045) were associated with worse OS on multivariate analysis. Low preoperative SA was associated with worse DFS and OS in patients with resected PDA. Lower BMI and SA were associated with longer post-operative hospital stay. Our study is one of the first to describe how pre-operative BMI and SA and post-operative changes in these variables impact clinical and perioperative outcomes. This data supports nutritional status and weight loss as predictors of outcome in resected pancreatic cancer patients and warrants further prospective investigation.

Indexed as

Body Mass IndexSerum AlbuminAdenocarcinomaAdultAgedDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedObesityPancreatic NeoplasmsRisk FactorsTreatment OutcomeSerum Albumin

Identifiers

PMID27015568
PMCPMC4807776
OpenAlexW2308451738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.